Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
SHANGHAI PECHEM
00338
5
SINOPEC CORP
00386
| (FY)Dec 31, 2025 | (Q4)Dec 31, 2025 | (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -46.08%-118.03K | -26.15%-11.02K | -137.97%-11.38K | -69.81%-80.31K | 72.00%-15.33K | -284.96%-80.8K | -141.41%-8.73K | -30.89%29.96K | -79.38%-47.3K | -1,075.23%-54.73K |
| Net income from continuing operations | -1.73%-2.27M | 2.89%-576.03K | -5.84%-568.75K | -5.84%-587.52K | 1.50%-533.97K | -11.61%-2.23M | -38.88%-593.15K | -2.56%-537.39K | -2.44%-555.09K | -7.78%-542.12K |
| Depreciation and amortization | -49.22%35.71K | -141.25%-11.69K | 12.86%15.8K | 12.86%15.8K | 12.86%15.8K | 24.80%70.33K | 309.20%28.33K | -39.91%14K | -39.91%14K | -39.91%14K |
| Other non cashItems | 0.32%2.08M | 0.55%523.92K | 0.56%523.92K | 0.55%518.58K | -0.40%513.65K | 0.32%2.07M | 0.26%521.03K | -0.01%521.02K | -0.01%515.72K | 1.03%515.71K |
| Change In working capital | 933.23%32.46K | 50.57%52.78K | -45.39%17.66K | -23.94%-27.17K | 74.48%-10.8K | 103.76%3.14K | 160.53%35.05K | 40.79%32.33K | 6.85%-21.93K | -68.06%-42.32K |
| -Change in receivables | 163.42%7.89K | 24.11%-38.29K | -224.89%-3.28K | 90.09%-176 | 33.60%49.63K | -143.73%-12.45K | -32.15%-50.45K | -90.68%2.62K | -101.72%-1.78K | 157.56%37.15K |
| -Change in prepaid assets | ---- | ---- | 0.00%3.75K | 0.00%-11.25K | 0.00%3.75K | --0 | 0.00%3.75K | 0.00%3.75K | 0.00%-11.25K | 0.00%3.75K |
| -Change in payables and accrued expense | 57.61%24.57K | 6.81%87.32K | -33.80%17.18K | -76.94%-15.75K | 22.87%-64.18K | 113.90%15.59K | 448.09%81.75K | 389.88%25.96K | 92.28%-8.9K | -333.67%-83.22K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -46.08%-118.03K | -26.15%-11.02K | -137.97%-11.38K | -69.81%-80.31K | 72.00%-15.33K | -284.96%-80.8K | -141.40%-8.73K | -30.89%29.96K | -79.38%-47.3K | -1,075.23%-54.73K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -10.50%-7.9K | 0 | 0.11%-896 | -12.00%-7K | 0 | 0.00%-7.15K | 100.11%1 | -897 | -6.25K | 0 |
| Net PPE purchase and sale | -10.50%-7.9K | --0 | 0.11%-896 | -12.00%-7K | --0 | 0.00%-7.15K | 100.11%1 | ---897 | ---6.25K | --0 |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -10.50%-7.9K | --0 | 0.11%-896 | -12.00%-7K | --0 | 0.00%-7.15K | 100.11%1 | ---897 | ---6.25K | --0 |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | ||||||||||
| Cash from discontinued financing activities | ||||||||||
| Net cash flow | ||||||||||
| Beginning cash position | -17.19%423.77K | -28.59%308.86K | -20.40%321.13K | -10.62%408.44K | -17.19%423.77K | 7.69%511.72K | -12.01%432.5K | -9.98%403.44K | -3.70%456.99K | 7.69%511.72K |
| Current changes in cash | -43.18%-125.93K | -26.17%-11.02K | -142.23%-12.27K | -63.06%-87.31K | 72.00%-15.33K | -340.69%-87.95K | -143.23%-8.73K | -32.96%29.06K | -103.08%-53.55K | -8,478.37%-54.73K |
| End cash Position | -29.72%297.84K | -29.72%297.84K | -28.59%308.86K | -20.40%321.13K | -10.62%408.44K | -17.19%423.77K | -17.19%423.77K | -12.01%432.5K | -9.98%403.44K | -3.70%456.99K |
| Free cash from | -43.18%-125.93K | -26.17%-11.02K | -142.23%-12.27K | -63.06%-87.31K | 72.00%-15.33K | -340.69%-87.95K | -143.23%-8.73K | -32.96%29.06K | -103.08%-53.55K | -8,478.37%-54.73K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.